Highlights of weekly biotech stock moves

Furiex Pharmaceuticals Inc. (NASDAQ:FURX) gained $3.34 (21%) to $19.10 last week after EMA accepted for review an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for alogliptin to treat Type II diabetes. The acceptance triggers a $10 million milestone payment to Furiex, which co-developed alogliptin with Syrrx Inc. Takeda acquired Syrrx in 2005.

Gilead Sciences Inc. (NASDAQ:GILD) was up $0.55 to $50.49 last week after EMA accepted for review an MAA for cobicistat as a boosting agent for HIV treatment with protease inhibitors. The application was submitted in April. Gilead plans to submit an application to FDA next quarter...